Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avisa Diagnostics Inc C.AVBT


Primary Symbol: FOGCF

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via its own delivery systems. Its ABT portfolio includes Post-Covid-19 Bronchiectasis, Develo, Ventilator-Associated Pneumonia (VAP), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired, Pneumonia (CAP), Cystic Fibrosis, Tuberculosis, Aspergillus Fungus and Clostridium Difficile (C. diff).


GREY:FOGCF - Post by User

Avisa Diagnostics Inc > We need some good news
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Post by Diomioon May 21, 2021 7:24am
144 Views
Post# 33246554

We need some good news

We need some good news1$ here we come
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities